NASDAQ:ALLO

Allogene Therapeutics Stock Forecast, Price & News

$21.95
-0.42 (-1.88 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$21.85
$22.59
50-Day Range
$21.61
$26.55
52-Week Range
$21.10
$44.92
Volume466,864 shs
Average Volume660,955 shs
Market Capitalization$3.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.09
30 days | 90 days | 365 days | Advanced Chart
Receive ALLO News and Ratings via Email

Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Allogene Therapeutics logo

About Allogene Therapeutics

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.40 out of 5 stars

Medical Sector

175th out of 2,220 stocks

Biological Products, Except Diagnostic Industry

24th out of 213 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Allogene Therapeutics (NASDAQ:ALLO) Frequently Asked Questions

Is Allogene Therapeutics a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Allogene Therapeutics stock.
View analyst ratings for Allogene Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Allogene Therapeutics?

Wall Street analysts have given Allogene Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Allogene Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Allogene Therapeutics' next earnings date?

Allogene Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Allogene Therapeutics
.

How can I listen to Allogene Therapeutics' earnings call?

Allogene Therapeutics will be holding an earnings conference call on Wednesday, August 4th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) issued its quarterly earnings data on Tuesday, May, 4th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.21. The company had revenue of $38.35 million for the quarter, compared to analyst estimates of $24.50 million.
View Allogene Therapeutics' earnings history
.

How has Allogene Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Allogene Therapeutics' stock was trading at $25.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALLO shares have decreased by 12.4% and is now trading at $21.95.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ALLO?

11 equities research analysts have issued 12-month price objectives for Allogene Therapeutics' stock. Their forecasts range from $41.00 to $55.00. On average, they expect Allogene Therapeutics' stock price to reach $46.13 in the next year. This suggests a possible upside of 110.1% from the stock's current price.
View analysts' price targets for Allogene Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Allogene Therapeutics' key executives?

Allogene Therapeutics' management team includes the following people:
  • David D. Chang, President, Chief Executive Officer & Director
  • Eric Schmidt, Chief Financial Officer
  • Barbra Sasu, Chief Scientific Officer
  • Alison Moore, Chief Technical Officer
  • Rafael G. Amado, Chief Medical Officer, EVP-Research & Development

What is David Chang's approval rating as Allogene Therapeutics' CEO?

2 employees have rated Allogene Therapeutics CEO David Chang on Glassdoor.com. David Chang has an approval rating of 100% among Allogene Therapeutics' employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Allogene Therapeutics' key competitors?

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

When did Allogene Therapeutics IPO?

(ALLO) raised $272 million in an IPO on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO.

What is Allogene Therapeutics' stock symbol?

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Who are Allogene Therapeutics' major shareholders?

Allogene Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Alliancebernstein L.P. (2.24%), Bourgeon Capital Management LLC (0.02%), Dupont Capital Management Corp (0.01%) and Cutler Group LP (0.00%). Company insiders that own Allogene Therapeutics stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Owen N Witte, Rafael Amado and Veer Bhavnagri.
View institutional ownership trends for Allogene Therapeutics
.

Which institutional investors are buying Allogene Therapeutics stock?

ALLO stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Bourgeon Capital Management LLC, Dupont Capital Management Corp, and Cutler Group LP.
View insider buying and selling activity for Allogene Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Allogene Therapeutics?

Shares of ALLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allogene Therapeutics' stock price today?

One share of ALLO stock can currently be purchased for approximately $21.95.

How much money does Allogene Therapeutics make?

Allogene Therapeutics has a market capitalization of $3.11 billion. The company earns $-250,220,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis.

How many employees does Allogene Therapeutics have?

Allogene Therapeutics employs 276 workers across the globe.

What is Allogene Therapeutics' official website?

The official website for Allogene Therapeutics is www.allogene.com.

Where are Allogene Therapeutics' headquarters?

Allogene Therapeutics is headquartered at 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Allogene Therapeutics?

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 457-2700 or via email at [email protected]


This page was last updated on 8/1/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.